Switching from oral medication, which your doctor may prescribe, is a big step. It's natural to have concerns. Hearing from others who’ve been down this road before you can be helpful.

Diabetes is complex with factors beyond your control

Living with type 2 diabetes is anything but predictable. It can change over time, and a treatment plan that once helped you may not be as effective going forward. Plus, your diabetes can be affected by factors beyond your control, like age, metabolism, and family history. So even if you’re trying to do everything right, including eating healthy foods and exercising regularly, your high A1c still may not budge. If you’re struggling to get your numbers down, it may be time to ask your doctor about changing from your current treatment to SOLIQUA 100/33.

Making the change from oral medications to injectable therapy

Meet Joanne. Type 2 diabetes runs in her family, yet she resisted making the change for years. But if she knew then what she knows now…

Read video transcript

JOANNE: If I knew then what I know now, I would have taken insulin sooner. They made it like it was a last resort. You take this and you have really messed up, and that’s not true.

Like certain diseases run in different families, and for me it’s like, “Who doesn't have diabetes?” you know? ‘Cause now it’s affecting my cousins, my first cousins and all, because our parents and grandparents. Even though the family history was there, nobody was really taking care of themselves or really understood what it was and was doing what they were supposed to do. So, needless to say, I kind of did the same thing for six years.

Look at my daughter, how cute…and she, too, now has type 2 diabetes, and she has an 8-year-old. But she went totally all out as to make sure he eats healthy. Her experience is totally different because he didn’t get anything sweet until he was a year old – a piece of cake. If I knew then what I know now, I’d tell her, “You’re going to be the one that has the child that breaks the cycle.”

And I’m proud to say…I helped her, yes. You're gonna have to make changes…and they’re not hard. It’s things that we should be doing anyway. …you know, It’s like taking on a new project. Do 60 percent, 70 percent. Get up to at least 80 percent to where you’re doing 80 percent right. Let’s hit the ground running with the education. Let’s change the way we’re eating.

Traditionally, being African-American, we go all out for the holidays, all right. You have a dessert table, the food. Do you need four or five meats? No. Do you need the chocolate cake, banana pudding, peach cobbler? Hecks no. What I did, I skipped the food and had all the desserts. So if I knew then what I know now, I would eat first, and then I’d have a little bit. Because we can have a little bit. You just cannot have a lot.

If I knew then what I know now, insulin would be one of the things that I would take. One of the tools that I would choose to use to help me with my diabetes. It’s gonna be a tool that you can take out of that toolbox and use. Now, of course, that’s not a miracle, that if you do this, you don't have to do anything else. You still have to eat healthy, you still have to exercise. I may ride a bike, I may lay on the floor pretendin’ like I’m doing yoga. I say pretendin’ because I don't know whether I’m doing it right or not. I’m doing it with the DVD. But I’m doing stuff.

Because look at me. I’m 68, I’m still here and I’m doing it.


SOLIQUA 100/33 helped 7 out of 10 people with Type 2 diabetes Uncontrolled on up to 2 oral therapies get to an A1c goal of 7% or below.

SOLIQUA 100/33 helps control blood sugar throughout the day and night.


In a clinical study of patients with type 2 diabetes (Lixilan O), 74% of patients using SOLIQUA 100/33 lowered their A1c below 7%, while 59% of patients on Lantus® (insulin glargine injection) 100 Units/mL and 33% of patients on lixisenatide reached an A1c below 7%. The A1c average was reduced from a starting point of 8.1% to 6.5% in patients taking SOLIQUA 100/33, from 8.1% to 6.8% in patients taking Lantus, and from 8.1% to 7.3% in patients taking lixisenatide at the end of 30 weeks.

Your doctor may prescribe a dose of insulin that is different from the doses used in the study. The results seen in the trial may not reflect your results.

Individual results may vary.

The clinical study (Lixilan O) showed that in patients treated with metformin, SOLIQUA 100/33 improved blood sugar control compared to its individual components, a long-acting insulin (Lantus), and a non-insulin, diabetes medicine (lixisenatide). The study included 1,479 patients with type 2 diabetes who were on metformin alone or a 2nd oral diabetes medication which was subsequently discontinued and whose A1c was not at goal. After 4 weeks of taking metformin alone, during which time the metformin dose was optimized, 1,170 patients who had still not achieved their A1c goal with A1c 7-10%, had a fasting blood sugar ≤250 mg/dL, and were on ≥1500 mg metformin continued in the study. For the next 30 weeks patients continued taking metformin and were also treated with either SOLIQUA 100/33 (469 patients), Lantus (467 patients), or lixisenatide (234 patients). In the patients receiving insulin glargine 100 units/mL in the form of Lantus or SOLIQUA 100/33, the insulin glargine dose was adjusted in accordance with fasting self-monitored blood glucose measures aiming for a target of (80-100 mg/dL) with a dose cap of 60 units in both the Lantus and SOLIQUA 100/33 groups. The study showed that combining lixisenatide with Lantus in SOLIQUA 100/33 can help lower blood sugar even further than its individual components in patients taking metformin.

Pay as little as $9* with the CO-PAY Card

Eligible commercially insured patients save on SOLIQUA 100/33: Pay as little as $9* for a 30-day supply.
*Maximum savings of $365 per pack. Terms & conditions apply.